[Thalidomide embryopathy 60 years]

Area of Science:

• Teratology
• Pharmacology
• Medical History

Background:

• Thalidomide, a sedative, was widely prescribed in the late 1950s and early 1960s.
• It was later recognized as a potent teratogen, causing severe congenital malformations.
• This review examines the historical context and lasting effects of thalidomide embryopathy.

Approach:

• Systematic analysis of historical data and case observations.
• Review of global incidence and long-term manifestations.
• Comparative analysis of regulatory responses in different countries.

Key Points:

• Thalidomide embryopathy resulted in a broad spectrum of birth defects across multiple organ systems.
• Over 10,000 global cases were documented, with approximately 2400 adults living with chronic late manifestations.
• The United States and German Democratic Republic (GDR) did not market thalidomide due to regulatory vigilance.

Conclusions:

• Thalidomide's teratogenic effects underscore the critical importance of rigorous drug safety evaluation.
• The historical impact of thalidomide embryopathy continues to influence modern pharmaceutical regulation.
• Understanding its legacy is crucial for preventing future drug-induced developmental toxicities.